INTRODUCTION {#gft524_s1}
============

Iron deficiency is highly prevalent in chronic kidney disease (CKD) patients \[[@GFT524C1]\]. After erythropoiesis-stimulating agents failed to improve cardiovascular disease burden among CKD patients in several recent large-scale randomized clinical trials \[[@GFT524C2]--[@GFT524C4]\], the idea of iron supplementation for anaemia treatment has re-gained interest in nephrology in recent years \[[@GFT524C5]\].

Iron supplementation may be provided either orally or intravenously. However, oral absorption of iron is poor in many CKD patients due to their chronic micro-inflammatory status with commensurately high hepcidin levels \[[@GFT524C6]\]. Hepcidin itself impairs intestinal iron absorption and transport from the enterocytes to the plasma \[[@GFT524C7]\].

Therefore the use of intravenous (*i.v.*) iron preparations has been recommended \[[@GFT524C8], [@GFT524C9]\]. Several *i.v.* iron preparations have been developed, most of which (like iron sucrose, ferric carboxymaltose, low-molecular-weight iron dextran and ferumoxytol) consist of a ferritin-like polynuclear, non-ionic ferric-oxyhydroxide core and a carbohydrate shell. Another *i.v.* iron preparation, iron isomaltoside 1000, differs in structure from these molecules, since it has been described as a matrix-like structure with interchanging layers of linear isomaltoside 1000 oligomers and iron atoms placed in cavities between, and within, the oligosaccharide molecules \[[@GFT524C10]\]. *I.v.* iron preparations vary in their carbohydrate ligands as well as in the chemistry of the coupling process and thus in physiochemical and pharmacokinetic parameters such as molecular weight, reactivity as well as thermodynamic stability \[[@GFT524C11]\]. These differences result in a substance-specific kinetic of non-transferrin-bound iron (NTBI; 'free iron') release from iron complexes after their *i.v.* administration \[[@GFT524C12]\]. Within the cell, NTBI can induce the formation of reactive oxygen species (ROS) \[[@GFT524C13], [@GFT524C14]\]. Oxidative stress, in turn, results in endothelial damage and dysfunction and triggers inflammation \[[@GFT524C15], [@GFT524C16]\]. Moreover, recent reports suggest that *i.v.* iron administration may impair the function of circulating leukocytes with subsequently increased susceptibility to bacterial infections \[[@GFT524C17]\]. Of note, most scientific work has focused on implications of 'free iron' on neutrophils \[[@GFT524C18]\], and only few reports have been published on interaction of 'free iron' with monocytes \[[@GFT524C19]\], despite the central role of monocytes in iron metabolism and host defence \[[@GFT524C20]\].

Moreover, previous research on iron toxicity has completely neglected the existence of monocyte heterogeneity, constituting a knowledge gap regarding the effects of *i.v.* iron preparations on different monocyte subsets. Three distinct monocyte subsets, namely, classical CD14^++^CD16^−^ monocytes, intermediate CD14^++^CD16^+^ monocytes and nonclassical CD14^+^CD16^++^ monocytes have been acknowledged by the recent consensus statement \[[@GFT524C21]\]. Intermediate monocytes are characterized as inflammatory and potentially proatherogenic cells; high cell counts of intermediate monocytes predict adverse cardiovascular outcome in CKD patients \[[@GFT524C22], [@GFT524C23]\].

Against this background, the purpose of this study was to investigate the immunoactivation of different monocyte subsets by five *i.v.* iron preparations which are commonly used in clinical nephrology, namely iron sucrose, ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol \[[@GFT524C24]\].

SUBJECTS AND METHODS {#gft524_s2}
====================

Subjects {#gft524_s2a}
--------

For our *in vitro* analysis, we recruited two groups of study participants:control subjects without overt CKD (depending on the analyses, three to seven subjects per experiment, as indicated below; all subjects had serum creatinine \<1.5 mg/dL), andpatients with severe CKD \[four patients with CKD stage G 4 - 5 (GFR\< 30 mL/min/1.73 m^2^) not yet on renal replacement therapy, and four haemodialysis patients\].

All participants gave informed consent. The study protocol was approved by the local Ethics Committee and was conducted in accordance with the Declaration of Helsinki.

Flow cytometric analysis {#gft524_s2b}
------------------------

Monocyte subsets were flow cytometrically identified in cell culture or in whole-blood assays according to our standardized and validated gating strategy using FACS Canto II with FACSDiva Software (BD Biosciences, Heidelberg, Germany) \[[@GFT524C22]\]. In brief, using a side scatter/CD86 dot plot, monocytes were detected as CD86-positive cells with monocytic scatter properties. Subsequently the three monocyte subsets classical, intermediate and nonclassical monocytes were gated based on their surface expression pattern of CD14 (LPS receptor) and CD16 (FcγIII receptor).

In the whole-blood assays we stimulated 150 µL blood with different *i.v.* iron preparations: iron sucrose (Venofer®), ferric carboxymaltose (ferinject®) (both from Vifor Pharma AG, Glattbrugg, Switzerland), iron isomaltoside 1000 (MonoFer®), low-molecular-weight iron dextran (CosmoFer®) (both from Pharmacosmos, Holbæk, Denmark) and ferumoxytol (Feraheme®, from AMAG Pharmaceuticals, Lexington, MA, USA).

All stimulations were done at 37°C and 5% CO~2~, and three iron concentrations were used: 0.133, 0.266 and 0.533 mg/mL.

Protein surface expression and intracellular cytokine production were quantified as mean fluorescence intensity (MFI). The following antibodies were used: anti-CD14 PerCP (Mφ9), anti-CD16 PeCy7 (3G8) and anti-CD195 APC (2D7/CCR5) and anti-TNF FITC (MAb11) (BD Biosciences, Heidelberg, Germany), anti-CD86 PE (HA5.2B7) (Beckman-Coulter, Krefeld, Germany), anti-CX~3~CR1 FITC (2A9-1) (Biozol, Eching, Germany), and anti-IL-1β Alexa Fluor® 647 (JK1B-1) (Biolegend, Fell, Germany).

Surface expression of CD14, CD16, CD86, CCR5 and CX~3~CR1 was determined after incubating 150 µL EDTA anticoagulated blood with iron preparations for 5 h.

For intracellular measurement of TNF-α and IL-1β, 150 µL Li-hep anticoagulated blood was incubated with iron preparations for 2 h before and for 1 h after addition of 350 µM of brefeldin A (Sigma-Aldrich, Taufkirchen, Germany). After staining for CD14, CD16 and CD86 and lysis, cells were fixed with paraformaldehyde (4%), washed with a saponin-containing buffer, stained with antibodies against TNF-α and IL-1β, washed and fixed with paraformaldehyde (1%).

*In vitro* generation of monocytes from haematopoietic CD34^+^ stem cells {#gft524_s2c}
-------------------------------------------------------------------------

For *in vitro* generation of monocytes, haematopoietic CD34^+^ stem cells were isolated and monocytes generated according to our standardized protocol (manuscript in preparation). Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from EDTA anticoagulated blood by Ficoll-Paque (Lymphocyte Separation Medium; PAA, Cölbe, Germany) gradient density centrifugation. CD34^+^ cells were isolated using the CD34 MicroBead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). For determining quality of isolation, CD34^+^ cells were stained with anti-CD34 APC (581; BD Biosciences) and anti-CD45 PE (HI30; BD Biosciences) antibodies. Mean purity assessed by flow cytometry was 85.3 ± 4.8%.

Isolated CD34^+^ haematopoietic stem cells were expanded in 6-well plates (1 × 10^4^ cells/mL) for 13 days in the Haematopoietic Progenitor Cell Expansion Medium DXF, enriched with Cytokine Mix E (PromoCell GmbH, Heidelberg, Germany). After expansion, cells were seeded in 12-well plates for differentiation to monocytes in the Haematopoietic Progenitor Medium (PromoCell GmbH) supplemented with iron preparations. Daily progress was flow cytometrically monitored after anti-CD14, anti-CD16 and anti-CD86 staining, subdividing cells into monocyte subsets. At Day 7 of differentiation, surface expression of CCR5 and CX~3~CR1 was additionally measured.

Measurement of ROS {#gft524_s2d}
------------------

For measurement of ROS, PBMCs were isolated from EDTA anticoagulated blood and stimulated with iron preparations for 3 h. Afterwards cells were incubated with 10 µM of the cell-permanent carboxy-H~2~DFFDA (Life technologies, Darmstadt, Germany) for 15 min at 37°C and 5% CO~2~. Samples were stained with CD14, CD16 and CD86 and the amount of ROS (MFI of H~2~DFFDA) was flow cytometrically determined as described above.

In analogy, for ROS determination of *in vitro* generated monocytes at Day 7 of differentiation, 200 µL of cell suspension was incubated with carboxy-H~2~DFFDA. Afterwards samples were stained and MFI-values were flow cytometrically calculated.

Phagocytosis assay {#gft524_s2e}
------------------

For measurement of monocytic phagocytosis capacity Fluoresbrite Yellow Green (YG) Carboxylate Microspheres (0.75 µm, Polysciences, Eppelheim, Germany) were opsonized with heterologous serum (mixed with Krebs Ringers PBS), adjusted to 10^8^ particles/mL and shaken gently for 30 min at 37°C. After stimulation of 150 µL of citrate anticoagulated blood with iron preparations for 4.5 h, 50 µL of opsonized particles were added and incubated for additional 30 min at 37°C with mild shaking. Samples were stained as described above, and counts of FITC-positive cells were determined flow cytometrically in each monocyte subset.

Within *in vitro* generated monocytes, phagocytosis capacity was measured at Day 7 of differentiation. Therefore, 90 µL of cell suspension was incubated with opsonized particles as described before.

Proliferation assay {#gft524_s2f}
-------------------

Monocyte subset-specific ability to induce T-cell proliferation was measured using the cytoplasmic dilution of CFDA-SE (Vybrant CFDA-SE Cell Tracer Kit; Life technologies). In detail, PBMCs were isolated from EDTA anticoagulated blood and labelled with 5 μM CFDA-SE for 10 min at 37°C. Cells were cultivated in 96-well plates at a density of 6 × 10^5^ cells and stimulated with iron preparations in the presence of 2.5 µg/mL staphylococcal enterotoxin B (SEB; Sigma-Aldrich). After 3 days, counts of proliferating T-cells were analysed flow cytometrically by measuring CFDA-SE dilution, identifying T-cells by anti-CD3 APC staining (SK7; Biolegend).

Measurement of iron uptake {#gft524_s2g}
--------------------------

For measurement of monocytic iron uptake, 150 µL of Li-hep anticoagulated blood was stimulated with iron preparations for 1 h. Samples were stained with antibodies against CD14, CD16 and CD86 as well as with calcein acetoxymethyl ester (Biomol, Hamburg, Germany) in a final concentration of 0.2 µM. Iron uptake was determined based on the ability of iron to bind calcein and to quench its fluorescence.

Determination of viability {#gft524_s2h}
--------------------------

For measurement of cellular viability, PBMCs were isolated from EDTA anticoagulated blood and stimulated with iron preparations for 3 h. Subsequently, samples were stained with Annexin V and 7-AAD in Annexin V Binding Buffer (FITC Annexin V Apoptosis Detection Kit with 7-AAD, Biolegend). Flow cytometrically, monocyte subsets were identified as described above, and viable cells were defined as 7-AAD-negative monocytes.

Statistics {#gft524_s2i}
----------

Statistical analysis was performed for each iron preparation using one-way analysis of variance (ANOVA), followed by Dunnett\'s multiple comparison test as *post hoc* test. Data were presented as percentages or MFI ± SEM (standard error of the mean).

RESULTS {#gft524_s3}
=======

Impact of iron preparations on human monocyte subsets {#gft524_s3a}
-----------------------------------------------------

We first aimed to analyse the impact of the three iron preparations iron sucrose, ferric carboxymaltose and iron isomaltoside 1000 on human monocyte subsets collected from control subjects without overt CKD. Therefore, we stimulated whole blood with the different iron preparations and analysed their effect on the expression of CD14, CD16 and CD86 on classical, intermediate and nonclassical monocytes. We found iron sucrose dose-dependently to increase CD86 surface expression on all monocyte subsets. In addition, we observed a significant reduction of CD16 expression on classical monocytes, and on nonclassical monocytes (Table [1](#GFT524TB1){ref-type="table"}). Despite this down-regulation of CD16 expression, no significant changes in monocyte subset distribution occurred (Figure [1](#GFT524F1){ref-type="fig"}), and CD14 expression did not change (Table [1](#GFT524TB1){ref-type="table"}). Ferric carboxymaltose and iron isomaltoside 1000 did not affect the expression of CD14, CD16 or CD86 (Table [1](#GFT524TB1){ref-type="table"}).Table 1.Expression of CD14, CD16 and CD86 on circulating mature classical, intermediate and nonclassical monocytes from control subjects Monocyte subsetControlIron sucroseFerric carboxymaltoseIron isomaltoside 10000.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mLCD14Classical monocytes5453 ± 3024766 ± 2585202 ± 2655166 ± 3605324 ± 4195469 ± 3285147 ± 3455194 ± 3185116 ± 3105094 ± 363Intermediate monocytes4842 ± 3494258 ± 3804385 ± 3383960 ± 2764503 ± 2754620 ± 2354554 ± 4154620 ± 4234512 ± 3674530 ± 384Nonclassical monocytes292 ± 25320 ± 37356 ± 23335 ± 23307 ± 31317 ± 39296 ± 27280 ± 24318 ± 35313 ± 31CD16Classical monocytes892 ± 119233 ± 43\*\*201 ± 43\*\*116 ± 24\*\*847 ± 70863 ± 94808 ± 90839 ± 81820 ± 74836 ± 84Intermediate monocytes6608 ± 12569159 ± 15987841 ± 15967348 ± 15308364 ± 22737556 ± 19027353 ± 15938186 ± 23008157 ± 19947425 ± 1697Nonclassical monocytes34 563 ± 102129 593 ± 177229 186 ± 190422 271 ± 2376\*\*31 979 ± 168034 913 ± 267131 873 ± 163733 687 ± 198231 530 ± 202733 258 ± 1785CD86Classical monocytes553 ± 51582 ± 36809 ± 49\*\*1291 ± 63\*\*551 ± 56552 ± 52540 ± 53551 ± 53535 ± 53541 ± 60Intermediate monocytes1100 ± 1281564 ± 1171881 ± 192\*\*2207 ± 154\*\*1202 ± 1861202 ± 1561200 ± 1431222 ± 1461262 ± 1541202 ± 154Nonclassical monocytes1419 ± 1481551 ± 1222047 ± 2412204 ± 249\*1376 ± 1381421 ± 1321397 ± 1311388 ± 1461355 ± 1221386 ± 131[^1][^2]FIGURE 1:Representative example of monocyte subset distribution after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM) or iron isomaltoside 1000 (ISM) (0.133, 0.266 and 0.533 mg/mL). Blood was collected from control subjects. Classical monocytes are shown in the upper left gate, intermediate monocytes in the upper right gate and nonclassical monocytes in the lower right gate of each dot plot. Statistical analysis was performed for each iron preparation using ANOVA, followed by Dunnett\'s multiple comparison test as *post hoc* test; data of seven independent experiments are presented as mean ± SEM.

Effect of iron preparations on monocytic chemokine receptor expression, inflammation response and functional characteristics {#gft524_s3b}
----------------------------------------------------------------------------------------------------------------------------

We analysed the effect of the three different iron preparations iron sucrose, ferric carboxymaltose and iron isomaltoside 1000 on subset-specific expression of chemokine receptors CCR5 and CX~3~CR1, on production of pro-inflammatory cytokines (TNF-α and IL-1β) and on ROS production. CX~3~CR1 expression was specifically and dose-dependently reduced by iron sucrose, while CCR5 expression was not. Moreover, iron sucrose tended to increase IL-1β and ROS production, but not TNF-α production. Ferric carboxymaltose and iron isomaltoside 1000 affected neither cytokine production, chemokine receptor expression nor ROS production significantly (Table [2](#GFT524TB2){ref-type="table"}).Table 2.Expression of CCR5 and CX~3~CR1 as well as production of TNF-α, IL-1β and ROS in circulating mature classical, intermediate and nonclassical monocytes from control subjects Monocyte subsetControlIron sucroseFerric carboxymaltoseIron isomaltoside 10000.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mLCCR5Classical monocytes76 ± 10115 ± 16102 ± 1882 ± 2573 ± 1077 ± 976 ± 977 ± 1076 ± 975 ± 8Intermediate monocytes297 ± 86369 ± 121340 ± 118277 ± 126303 ± 100284 ± 82285 ± 96300 ± 91311 ± 93290 ± 91Nonclassical monocytes99 ± 19115 ± 2499 ± 2363 ± 2894 ± 2096 ± 1288 ± 1395 ± 1980 ± 1195 ± 16CX~3~CR1Classical monocytes1138 ± 73845 ± 57\*\*660 ± 50\*\*496 ± 35\*\*1156 ± 871158 ± 751164 ± 801190 ± 751242 ± 731202 ± 86Intermediate monocytes2180 ± 2091755 ± 1981505 ± 189\*1130 ± 120\*\*2221 ± 2062160 ± 2292180 ± 1962310 ± 2542341 ± 2752708 ± 467Nonclassical monocytes4860 ± 2314141 ± 2933368 ± 303\*\*2697 ± 223\*\*4922 ± 2664863 ± 2524815 ± 2044904 ± 1894946 ± 1824827 ± 348TNF-αClassical monocytes168 ± 30140 ± 20123 ± 14119 ± 14185 ± 32191 ± 36191 ± 30183 ± 40182 ± 36182 ± 32Intermediate monocytes183 ± 29216 ± 44181 ± 26177 ± 27207 ± 34228 ± 47205 ± 35220 ± 36189 ± 39187 ± 20Nonclassical monocytes125 ± 18162 ± 19141 ± 16131 ± 15148 ± 21148 ± 23144 ± 20155 ± 23142 ± 23145 ± 17IL-1βClassical monocytes73 ± 19133 ± 38128 ± 35148 ± 4085 ± 1284 ± 1282 ± 1595 ± 1993 ± 2392 ± 31Intermediate monocytes122 ± 26173 ± 46168 ± 28169 ± 28137 ± 28160 ± 32137 ± 32162 ± 39136 ± 30123 ± 24Nonclassical monocytes90 ± 15112 ± 2389 ± 1289 ± 14108 ± 14104 ± 11105 ± 14110 ± 15104 ± 15103 ± 17ROSClassical monocytes2899 ± 6843403 ± 7673503 ± 7813449 ± 7693043 ± 6913260 ± 7063252 ± 7183201 ± 8223403 ± 8733613 ± 937Intermediate monocytes3760 ± 8984758 ± 12664400 ± 8934687 ± 9893973 ± 9874173 ± 9484264 ± 10244184 ± 11584351 ± 11414768 ± 1321Nonclassical monocytes3179 ± 8063795 ± 10264011 ± 11053784 ± 10273248 ± 8783503 ± 9223554 ± 9703531 ± 11033686 ± 11523972 ± 1233[^3][^4]

Next, we tested the effect of iron preparations on the main functional characteristics of monocytes, namely phagocytosis capacity and antigen presentation (via analysis of T-cell proliferation). In contrast to ferric carboxymaltose and iron isomaltoside 1000, iron sucrose significantly reduced the capacity of classical monocytes to phagocyte microspheres (Figure [2](#GFT524F2){ref-type="fig"}A). T-cell proliferation tended to be decreased after stimulation with the highest dosage of iron sucrose, but tended to be increased after stimulation with lower dosages of iron sucrose, ferric carboxymaltose and iron isomaltoside 1000 (Figure [2](#GFT524F2){ref-type="fig"}B). To prove biological plausibility of these results, we first excluded that the effects of iron sucrose are caused by increased apoptosis of monocytes (Figure [3](#GFT524F3){ref-type="fig"}A), and next showed that iron sucrose is more avidly taken up by monocytes than ferric carboxymaltose or iron isomaltoside 1000 (Figure [3](#GFT524F3){ref-type="fig"}B), which may account for the preparation-specific effects of iron sucrose on monocyte function.FIGURE 2:(**A**). Representative example of classical monocytes to phagocyte opsonized carboxylate microspheres (0.75 µm, Yellow Green) within 30 min after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM) or iron isomaltoside 1000 (IIM) (0.133, 0.266 and 0.533 mg/mL). Blood was collected from control subjects. Counts of FITC-positive cells (upper population) were determined flow cytometrically and statistical analysis was performed for each iron preparation by using ANOVA followed by Dunnett\'s multiple comparison test as *post hoc* test; data of six independent experiments are presented as mean ± SEM. (**B**). Flow cytometric analysis of T-cell proliferation after stimulation with staphylococcal enterotoxin B (SEB) (2.5 µg/mL) and the different iron preparations iron sucrose (IS), ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) (0.133, 0.266 and 0.533 mg/mL) for 3 days. Blood was collected from control subjects. Statistical analysis was performed for each iron preparation by using ANOVA followed by Dunnett\'s multiple comparison test as *post hoc* test; data of seven independent experiments are presented as mean ± SEM.FIGURE 3:(**A**) Flow cytometric analysis of monocytic viability after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM) or iron isomaltoside 1000 (IIM) (0.133, 0.266 and 0.533 mg/mL) by 7-AAD staining. Blood was collected from control subjects. Statistical analysis was performed for each iron preparation by using ANOVA and the Dunnett\'s multiple comparison test as *post hoc* test; data of five independent experiments are presented as mean ± SEM. (**B**). Flow cytometric calcein assay for the analysis of the iron content in classical, intermediate and nonclassical monocytes after stimulation of whole blood for 1 h with iron sucrose (IS), ferric carboxymaltose (FCM) or iron isomaltoside 1000 (IIM) (0.133, 0.266 and 0.533 mg/mL). As iron intracellularly binds calcein and quenches its fluorescence, lower fluorescence intensity represents higher intracellular iron content. Blood was collected from control subjects. Data were measured as mean fluorescence intensity (MFI). Statistical analysis was performed using ANOVA and the Dunnett\'s multiple comparison test as *post hoc* test; data of six independent experiments are presented as mean ± SEM; \*\*P \< 0.01.

Impact of iron preparations on monocyte differentiation {#gft524_s3c}
-------------------------------------------------------

In order to test whether specific iron preparations (iron sucrose, ferric carboxymaltose and iron isomaltoside 1000) differently affect development of monocytes, we analysed *in vitro* differentiation of isolated CD34^+^ haematopoietic stem cells into classical and intermediate monocytes. Iron sucrose significantly reduced *in vitro* differentiation into intermediate monocytes even at the lowest dose (Figure [4](#GFT524F4){ref-type="fig"}), which is mirrored by a strongly decreased CD14 and CD16 expression on these cells (Table [3](#GFT524TB3){ref-type="table"}). Simultaneously it significantly increased CD86 expression on *in vitro* differentiated monocytes, which is in line with its effect on circulating mature monocytes. Although a significant reduction of CD14 on classical monocytes was observed after stimulation with ferric carboxymaltose and iron isomaltoside 1000, these iron preparations affected neither *in vitro* differentiation of monocyte subsets nor their expression of CD16 and CD86.Table 3.Expression of CD14, CD16 and CD86 on classical and intermediate monocytes after differentiation from haematopoietic stem cells from control subjects Monocyte subsetControlIron sucroseFerric carboxymaltoseIron isomaltoside 10000.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mLCD14Classical monocytes10 546 ± 3946835 ± 702\*7027 ± 5366088 ± 1474\*7329 ± 218\*\*7050 ± 264\*\*7842 ± 726\*\*8352 ± 4697376 ± 430\*\*8528 ± 830Intermediate monocytes25 929 ± 271319 929 ± 82018 009 ± 348\*17 709 ± 1948\*19 417 ± 102219 272 ± 80120 952 ± 199121 481 ± 157919 247 ± 142920 862 ± 2394CD16Classical monocytes1147 ± 33867 ± 32\*\*769 ± 60\*\*630 ± 35\*\*1335 ± 881342 ± 1211316 ± 811232 ± 1401272 ± 821177 ± 104Intermediate monocytes5549 ± 6386462 ± 1035654 ± 4454806 ± 4755125 ± 3555173 ± 2255227 ± 867327 ± 15455801 ± 835364 ± 164CD86Classical monocytes838 ± 106945 ± 151259 ± 110\*1659 ± 91\*\*940 ± 118964 ± 102894 ± 60707 ± 57779 ± 54762 ± 19Intermediate monocytes3178 ± 5503074 ± 4623370 ± 3803654 ± 8163819 ± 5633814 ± 5553233 ± 2852751 ± 423011 ± 1992834 ± 170[^5][^6]FIGURE 4:*In vitro* differentiation of haematopoietic CD34^+^ stem cells into classical and intermediate monocytes after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM) or iron isomaltoside 1000 (IIM) \[0.133 mg/mL (**A**), 0.266 mg/mL (**B**) and 0.533 mg/mL (**C**)\]. Iron preparations were added at Day 0. Blood was collected from control subjects. Statistical analysis was performed using ANOVA and the Dunnett\'s multiple comparison test as *post hoc* test; data of three independent experiments are presented as mean ± SEM; \*P \< 0.05, \*\*P \< 0.01.

Implication of iron preparations on characteristics of *in vitro*-differentiated monocytes {#gft524_s3d}
------------------------------------------------------------------------------------------

We then determined the expression of CCR5 and CX~3~CR1, as well as ROS production, by *in vitro* differentiated monocyte subsets (Table [4](#GFT524TB4){ref-type="table"}). CX~3~CR1 expression was increased after treatment with iron sucrose and ferric carboxymaltose, whereas CCR5 expression and ROS production were not significantly altered.Table 4.Expression of CCR5 and CX~3~CR1 and ROS production by *in vitro* differentiated classical and intermediate monocytes from control subjects Monocyte subsetControlIron sucroseFerric carboxymaltoseIron isomaltoside 10000.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mL0.133 mg/mL0.266 mg/mL0.533 mg/mLCCR5Classical monocytes643 ± 154433 ± 62418 ± 44337 ± 5599 ± 112547 ± 107551 ± 110508 ± 115519 ± 97524 ± 116Intermediate monocytes1365 ± 1951274 ± 1031135 ± 133862 ± 151326 ± 1421291 ± 1391285 ± 1901246 ± 1201247 ± 1421278 ± 219CX~3~CR1Classical monocytes3982 ± 3705936 ± 3866057 ± 6783308 ± 5104980 ± 1175481 ± 164\*5415 ± 326\*5304 ± 10855029 ± 5884731 ± 463Intermediate monocytes5602 ± 42010 118 ± 491\*10 906 ± 957\*\*7885 ± 11486961 ± 183\*7612 ± 182\*\*7506 ± 395\*\*7869 ± 19437064 ± 7186570 ± 483ROSClassical monocytes2714 ± 9197471 ± 26228710 ± 303210 715 ± 41865104 ± 18885550 ± 21585831 ± 21473697 ± 11604103 ± 13844959 ± 1724Intermediate monocytes3628 ± 114110 642 ± 387712 392 ± 480211 998 ± 50967231 ± 25477635 ± 28208783 ± 31025347 ± 15805910 ± 18867044 ± 2453[^7][^8]

Finally, *in vitro* differentiated classical and intermediate monocytes displayed a dose-dependent reduction in their phagocytosis capacity after iron sucrose treatment, even though the level of significance was not reached (data not shown).

Impact of iron preparations on human monocyte subsets from CKD patients {#gft524_s3e}
-----------------------------------------------------------------------

We next analysed (i) whether these observed effects of iron sucrose can be transferred from control subjects without overt CKD to patients with severe CKD and (ii) whether two other iron preparations, namely low-molecular-weight iron dextran and ferumoxytol, induce monocyte activation similar to iron sucrose.

We first found iron sucrose to dose-dependently increase CD86 surface expression on classical and intermediate monocytes and to significantly reduce CD16 expression on classical monocytes, whereas monocyte subset distribution and CD14 expression were not changed (Figure [5](#GFT524F5){ref-type="fig"}, [Supplementary Table S1](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft524/-/DC1)). Ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol affected neither monocyte subset distribution nor expression of CD14, CD16 or CD86 on monocyte subsets ([Supplementary Table S1](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft524/-/DC1)).FIGURE 5:Representative example of monocyte subset distribution after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM), iron isomaltoside 1000 (ISM), low-molecular-weight iron dextran (ID) and ferumoxytol (FO) (0.133, 0.266 and 0.533 mg/mL). Blood was collected from patients with severe CKD. Classical monocytes are shown in the upper left gate, intermediate monocytes in the upper right gate and nonclassical monocytes in the lower right gate of each dot plot. Statistical analysis was performed for each iron preparation using ANOVA, followed by Dunnett\'s multiple comparison test as *post hoc* test; data of eight independent experiments are presented as mean ± SEM.

Effect of iron preparations on monocytic chemokine receptor expression and functional characteristics on monocytes from CKD patients {#gft524_s3f}
------------------------------------------------------------------------------------------------------------------------------------

CX~3~CR1 expression was dose-dependently reduced by iron sucrose, while CCR5 expression and ROS production were not significantly altered. Ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol affected neither chemokine receptor expression nor ROS production ([Supplementary Table S1](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft524/-/DC1)).

Next, we found a significant reduction of the phagocytosis capacity of classical monocytes after stimulation with iron sucrose (Figure [6](#GFT524F6){ref-type="fig"}A). Moreover, T-cell proliferation was heterogeneously affected by different iron preparations in different dosages (Figure [6](#GFT524F6){ref-type="fig"}B). Finally, compared with the other four iron preparations, iron sucrose is more avidly taken up by monocytes as found in the calcein assay ([Supplementary Figure S1](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft524/-/DC1)).FIGURE 6:(**A**) Representative example of classical monocytes to phagocyte opsonized carboxylate microspheres (0.75 µm, Yellow Green) within 30 min after stimulation with iron sucrose (IS), ferric carboxymaltose (FCM), iron isomaltoside 1000 (IIM), low-molecular-weight iron dextran (ID) and ferumoxytol (FO) (0.133, 0.266 and 0.533 mg/mL). Blood was collected from patients with severe CKD. Counts of FITC-positive cells (upper population) were determined flow cytometrically and statistical analysis was performed for each iron preparation by using ANOVA followed by Dunnett\'s multiple comparison test as *post hoc* test; data of eight independent experiments are presented as mean ± SEM. (**B**). Flow cytometric analysis of T-cell proliferation after stimulation with staphylococcal enterotoxin B (SEB) (2.5 µg/mL) and the different iron preparations iron sucrose (IS), ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM), low-molecular-weight iron dextran (ID) and ferumoxytol (FO) (0.133, 0.266 and 0.533 mg/mL) for 3 days. Blood was collected from patients with severe CKD. Statistical analysis was performed for each iron preparation by using ANOVA followed by Dunnett\'s multiple comparison test as *post hoc* test; data of eight independent experiments are presented as mean ± SEM; \*P \< 0.05, \*\*P \< 0.01.

In summary, effects of iron sucrose on monocytes from patients with severe CKD were in line with effects observed in monocytes from subjects without overt CKD. For technical reasons we did not analyse *in vitro* differentiation of monocytes from haematopoietic CD34^+^ stem cells and monocytic viability.

DISCUSSION {#gft524_s4}
==========

Use of *i.v.* iron preparations for anaemia treatment has attracted substantial interest in recent years. Despite an inverse association between haemoglobin levels and cardiovascular event rate \[[@GFT524C25], [@GFT524C26]\] and mortality \[[@GFT524C27]\] in observatory studies, large intervention trials that used erythropoietin or other erythropoietin-stimulating agents (ESA) for normalizing haemoglobin levels in CKD patients failed to reduce cardiovascular events and death. Therefore, recent KDIGO consensus guidelines advocate the use of iron supplements with the aim both to increase haemoglobin and to reduce ESA doses \[[@GFT524C1]\]. Moreover KDIGO guidelines acknowledge the need for *i.v.* iron supplements in dialysis patients, in whom gastrointestinal absorption of oral iron supplements is generally poor \[[@GFT524C1]\].

The increasing use of *i.v.* iron preparations necessitates a critical analysis of their side effects \[[@GFT524C28], [@GFT524C29]\], which are mainly attributed to the abruptly increasing amount of NTBI ('free iron') after *i.v.* iron infusion.

It has long been acknowledged that *i.v.* iron preparations impair leukocyte immune function and trigger bacterial infections \[[@GFT524C17]\]. Interestingly, previous experimental work focussed on the effect of *i.v.* iron preparations on neutrophil biology, whereas their impact on monocytes received little interest in the past.

Against this background, we now analysed the effect of the three different *i.v.* iron preparations, iron sucrose, ferric carboxymaltose and iron isomaltoside 1000, in both therapeutically recommended and supratherapeutic dosages on monocytes from control subjects *in vitro*. To verify the relevance of these effects in clinical nephrology, we further tested the immunological *in vitro* effects of these three preparations on monocytes collected from patients with severe CKD; this additionally allowed us to test two further preparations, namely low-molecular-weight iron dextran and ferumoxytol. Iron sucrose induced significant changes in monocytic immune function, which occurred even at lower, therapeutically recommended dosages, whereas ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol had no relevant effects at any dosage. We first found that iron sucrose changed expression of CD16, without affecting subset distribution of mature circulating monocytes. In differentiation experiments, the reduced CD16 expression after *i.v.* iron sucrose stimulation occurred in conjunction with a dose-dependent inhibition of stem cell differentiation into classical and intermediate monocytes.

We next assessed the effect of iron stimulation on specific characteristics of intermediate monocytes, namely cytokine and ROS production and chemokine receptor expression. We hereby firstly confirmed that intermediate monocytes have the highest capacity to produce pro-inflammatory cytokines \[[@GFT524C30]\] and ROS \[[@GFT524C22]\]. Next, we found that iron sucrose tended to increase IL-1β and ROS production. Interestingly, Martin-Malo *et al.* reported that iron sucrose and ferric carboxymaltose increased percentages of ROS-producing cells and apoptotic cells both *in vitro*---in PBMCs from healthy donors and patients CKD stage 5---and *in vivo* during haemodialysis sessions \[[@GFT524C31]\].

While intermediate monocytes are prone to production of pro-inflammatory cytokines and ROS, and to antigen presentation, classical monocytes have the highest phagocytosis capacity \[[@GFT524C32]\], which is verified in the present analysis. Confirming our hypothesis of an impaired monocytic function after iron sucrose stimulation, we found a dose-dependent reduction of phagocytosis even at the lowest dose. This effect is in line with previous studies testing the effect of iron sucrose on phagocytosis capacity of polymorphonuclear leukocytes \[[@GFT524C17], [@GFT524C33]\].

Taken together, only iron sucrose impaired monocytic functions *in vitro*. This may result from pharmacokinetic differences between *i.v.* iron preparations, which differ in their carbohydrate ligands, consequently their structural build-up, distinct molecular weights (iron sucrose: 140 100 Da, ferric carboxymaltose: 233 100 Da, iron isomaltoside 1000: 150 000 Da, low-molecular-weight iron dextran: 165 000 Da, ferumoxytol: 275 700 Da) \[[@GFT524C10]\] and half-lives (iron sucrose: 5.3 h; ferric carboxymaltose: 7.4--9.4 h, iron isomaltoside 1000: 23.2 h, low-molecular-weight iron dextran: 27--30 h, ferumoxytol: 14.7 h) \[[@GFT524C34], [@GFT524C35]\]. Among those iron preparations, iron sucrose has the lowest molecular weight, the shortest half-life and the lowest stability, which in conjunction determine the amount and the kinetic of free iron release. Moreover, in relation to the size of the iron particles, iron sucrose has the highest content of labile iron when compared with the other iron preparations \[[@GFT524C10], [@GFT524C36]\]. It is proposed that stable *i.v.* iron preparations, like ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol, release few NTBI and are mainly taken up as complex by phagocytosis \[[@GFT524C37]\]. In contrast, less stable iron preparations, such as iron sucrose, release higher levels of NTBI. Even though most of this free iron is taken up by transferrin and other proteins, some amount of NTBI may directly be taken up in an unregulated way by different cell types or freely translocate across cell membranes \[[@GFT524C34], [@GFT524C38], [@GFT524C39]\]. Intracellularly, 'free iron' constitutes the labile iron pool, consisting of iron that is not linked to its storage protein ferritin \[[@GFT524C13], [@GFT524C38]\]. This labile iron pool may induce distinct toxic effects such as ROS production and subsequently DNA damage and lipid peroxidation \[[@GFT524C40], [@GFT524C41]\].

In our work, we were able to demonstrate a more rapid uptake of iron sucrose compared with ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol in all three monocyte subsets, using the calcein assay. These results are in line with the findings of Sonnweber *et al.* \[[@GFT524C19]\], who had shown that *i.v.* injected iron sucrose is taken up by monocytes and increases circulating ferritin levels resulting in an impaired monocytic immune function, cytokine expression and activation of the NF-κB pathway.

Our study has several limitations. In most experiments, we incubated whole blood or blood cells only for 5 h for technical reasons: previous experiments have shown that monocyte subsets change their surface marker expression after a longer incubation period *in vitro.* This particularly affects surface expression of CD16, which renders flow cytometric distinction of monocyte subsets impossible. This short incubation time might have biased our study results, as monocyte effects of ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol may become evident only after longer incubation. Nonetheless, even those experiments that lasted several days, e.g. *in vitro* differentiation of haematopoietic stem cells into monocytes, pointed towards a particular effect of iron sucrose on monocyte biology.

As a further limitation, we cannot formally prove the biological relevance of our study results. We deliberately chose to focus our study on *in vitro* effects of iron on mature circulating monocytes and haematopoietic stem cells. *In vivo* monocytes might be exposed to lower iron concentrations than in our *in vitro* analysis, after iron complexes may rapidly be taken up *in vivo* by cells of the reticuloendothelial system via endocytosis \[[@GFT524C37]\].

Nonetheless, given that monocytes are the central regulators of the innate immune systems, and that CKD by itself negatively affects monocytic functions, we are confident that repetitive infusion of iron sucrose for treatment of anaemia in CKD may be considered as potentially immunoactivating. To further unravel the biological impact of different iron preparations, a randomized controlled trial with clinical end-points comparing iron sucrose and other *i.v.* iron preparations would be informative. Nonetheless, until such a trial will be initiated, *in vitro* data will be necessary in order to better appreciate the risk of distinct iron preparations.

Taken together, when comparing the *i.v.* iron preparations iron sucrose, ferric carboxymaltose, iron isomaltoside 1000, low-molecular-weight iron dextran and ferumoxytol, we found strong and selective immunologic effects of iron sucrose on monocyte subsets even at pharmacological dosages. These findings underscore the notion that each specific *i.v.* iron preparations may exert particular biological functions and may confer specific side effects.
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[^1]: Indicated are mean fluorescence intensity \[MFI\] ± SEM; *n* = 7

[^2]: \*P \< 0.05, \*\*P \< 0.01

[^3]: Indicated are mean fluorescence intensity \[MFI\] ± SEM; *n* = 7 for analysis of CCR5 and CX~3~CR1 expression, *n* = 4 for analysis of TNF-α and IL-1β production, *n* = 6 for analysis of ROS production

[^4]: \*P \< 0.05, \*\*P \< 0.01

[^5]: Indicated are mean fluorescence intensity \[MFI\] ± SEM; *n* = 3

[^6]: \*P \< 0.05, \*\*P \< 0.01

[^7]: Indicated are mean fluorescence intensity \[MFI\] ± SEM; *n* = 3

[^8]: \*P \< 0.05, \*\*P \< 0.01
